Skip to main content
. 2012 Aug 14;107(6):956–960. doi: 10.1038/bjc.2012.353

Figure 1.

Figure 1

Serum collection in the HER2-positive patient cohort in the GeparQuinto trial. Abbreviations: C=cyclophophamide; E=epirubicin; H=trastuzumab; L=lapatinib and T=docetaxel.